Key facts
- It has raised $66.6M; the latest was Early Stage VC ($7.2M) in Feb 2026.
- Notable investors include GL Ventures, CDH Investments, Tencent Investment, Pudong Capital, Shanghai Pudong Venture Capital — 21 tracked in total.
- Status: Privately Held (backing).
Investors
21+- ·The complete investor list — 21 names
- ·Watchlist + deal alerts for UniXell Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for UniXell Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About UniXell Biotechnology
Developer of cellular therapy designed for human pluripotent stem cells. The company offers unmet medical needs, including neurodegenerative diseases and rare diseases, and it has developed multiple key technology platforms, including reprogramming technology, stem cell differentiation, SISBAR pedigree tracing technology and high-precision gene editing, thereby providing effective treatment solutions for patients afflicted with neurodegenerative disorders, rare diseases, and tumors.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2021
- Employees
- 40
- Website
- unixell.com/
- Ownership
- Privately Held (backing)
UniXell Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in UniXell Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on UniXell Biotechnology in its N-PORT filings yet. We sweep new filings monthly.